A Study of LY3549492 in Participants With Type 2 Diabetes Mellitus (T2DM)

Diabetes Mellitus, Type 2 Clinical Trial

Official title:

A Randomized, Double-Blind, Multiple-Ascending Dose, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3549492 in Patients With Type 2 Diabetes Mellitus

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05327595
• Other study ID #: 18188
• Secondary ID: J3H-MC-GZNB2021-
• Status: Completed
• Phase: Phase 1
• Start date: May 9, 2022
• Est. completion date: April 22, 2024

Study information

• Verified date: May 2024
• Source: Eli Lilly and Company
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The main purpose of this study is to evaluate the safety and tolerability of LY3549492 in participants with T2DM. Blood tests will be done to check how much LY3549492 gets into the bloodstream and how the body handles LY3549492. This study has two parts. Each participant will enroll in only one part. The study will last either 12 or 13 weeks, depending on part.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 80
• Est. completion date: April 22, 2024
• Est. primary completion date: April 22, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Participants with T2DM for at least 6 months, as defined by the American Diabetes Association or the World Health Organization,
• treated with diet and exercise and stable dose(s) of metformin, with or without 1 other oral antidiabetic medication (OAM) at stable dose, 3 months prior to study entry
• If taking statins, must be on stable statin treatment without a history of statin myopathy for at least 3 months
• with a glycated hemoglobin (HbA1c) value of
• greater than or equal to (=)6.5 percent (%) and less than or equal to (=)10.5% at screening on metformin only and
• =6.5% and =9.5% on metformin in combination with OAMs other than metformin.
• Body weight =45.0 kilograms (kg) and body mass index within the range of 18.5 to 45.0 kilogram per square meter (kg/m²) (inclusive).
• Stable body weight for the 3 months prior to screening
• Women must not be of childbearing potential.

Exclusion Criteria:

• Women of childbearing potential.
• Have type 1 diabetes mellitus, known latent autoimmune diabetes in adults, or have had an episode of ketoacidosis or hyperosmolar state requiring hospitalization in 6 months prior to screening.
• Have active proliferative diabetic retinopathy, diabetic maculopathy, or severe nonproliferative diabetic retinopathy that requires acute treatment
• Present with uncontrolled comorbid conditions commonly associated with diabetes (for example, hypertension, hypercholesterolemia) or have had changes to medication for those conditions within 1 month prior to screening.
• Have had an episode of severe hypoglycemia, as defined by the occurrence of neuroglycopenic symptoms requiring the assistance of another person for recovery, within 6 months prior to screening visit, or have a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms. Any participant that the investigator feels will not be able to communicate an understanding of hypoglycemic symptoms and the appropriate treatment of hypoglycemia should also be excluded.
• Have a known clinically significant gastric emptying abnormality (for example, severe diabetic gastroparesis or gastric outlet obstruction), have undergone gastric bypass (bariatric) surgery or restrictive bariatric surgery (for example, gastric banding ), and/or device-based therapy for obesity, or have had device removal within the past 6 months.
• Have active or symptomatic gastric ulceration or chronic gastritis.
• Have evidence of hypothyroidism or hyperthyroidism based on clinical evaluation or an abnormal thyroid stimulating hormone (for those with current or previous thyroid history) that, in the opinion of the investigator, would pose a risk to participant safety.
• Have known definitive diagnosis of autonomic neuropathy as evidenced by neuropathic urinary retention, resting tachycardia, orthostatic hypotension, or diabetic diarrhea.
• Have obesity induced by other endocrine disorders such as Cushing's syndrome or Prader-Willi syndrome.
• A history of additional risk factors for Torsades de Pointes (for example, heart failure, hypokalemia, family history of long QT syndrome, use of concomitant medications that prolong the QT/QTc interval).
• Have an abnormality in the 12-lead electrocardiogram (ECG) at screening that, in the opinion of the investigator, increases the risks associated with participating in the study or may confound ECG data analysis
• Have a significant history (within the past 6 months) of or current comorbidities capable of altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study drug; or of interfering with the interpretation of data. These include cardiovascular, respiratory diseases, renal diseases, gastrointestinal (GI) diseases, hematological diseases, neurological diseases, dermatological diseases
• Have a history or presence of pancreatitis (history of chronic pancreatitis or idiopathic acute pancreatitis), elevation in serum amylase or lipase levels (>2.5 fold the upper limit of normal [ULN]).
• Have a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
• Have a serum calcitonin level of
• =20.0 picograms per milliliter (pg/mL) at screening, if estimated glomerular filtration rate is =60 milliliters per minute per 1.73 m² (mL/min/1.73 m²)
• =35.0 pg/mL at screening, if estimated glomerular filtration rate is <60 mL/min/1.73 m²
• Have known liver disease, obvious clinical signs or symptoms of liver disease, acute or chronic hepatitis, or have elevations in aminotransferases (alanine transaminase [ALT] and aspartate aminotransferase [AST]) greater than 2 × ULN.
• Have total bilirubin level (TBL) >1.5 × ULN (except for participants diagnosed with Gilbert's syndrome).

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 2

Intervention

Drug:
• LY3549492
Administered orally.
• Placebo
Administered orally.
• Atorvastatin
Administered orally.
• Midazolam
Administered orally.

Locations

Country	Name	City	State
Germany	Profil Institut für Stoffwechselforschung	Neuss

Sponsors (1)

Lead Sponsor	Collaborator
Eli Lilly and Company

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration	A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module	Baseline through final follow-up at approximately Day 49
Secondary	Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3549492	PK: AUC of LY3549492	Day 1 predose up to Day 35
Secondary	PK: Maximum Concentration (Cmax) of LY3549492	PK: Cmax of LY3549492	Day 1 predose up to Day 35
Secondary	Pharmacodynamics (PD): Change from Baseline to Day 28 in Fasting Glucose	PD: Change from Baseline to Day 28 in Fasting Glucose	Baseline, Day 28
Secondary	PD: Change from Baseline to Day 28 in Oral Glucose Tolerance (OGTT) 2 Hour Glucose	PD: Change from Baseline to Day 28 in OGTT 2 Hour Glucose	Baseline, Day 28